Clinical Trial Update: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluating safety and biological effects of orally administered reparixin in early breast cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-03-25